Simplex Realty develops residential and commercial real estate projects in Mumbai and Goa, earning revenue through the sale of completed units and redevelopment of housing societies.
The company lacks a sustainable competitive advantage, as evidenced by an average ROCE of just 0.3% and negative ROE. Real estate development in Mumbai is highly fragmented and competitive, and the company's small scale prevents it from achieving cost or brand advantages.
Capital allocation has been poor, with significant funds tied up in low-yielding inter-corporate deposits and investments in struggling associate companies like Simplex Papers, whose net worth is fully eroded. Reinvested capital has failed to generate returns above the cost of capital.
The company's demise was driven by the total evaporation of capital through its associate, Simplex Papers, and the continued misallocation of cash into low-yield inter-corporate deposits rather than productive real estate assets. While revenue growth appeared strong on paper, the inability to convert sales into actual cash flow or meaningful returns on equity led to a liquidity crunch. The concentration of capital in disputed projects with capitalized legal fees eventually resulted in write-downs, leaving shareholders with a shell of a business that prioritized related-party interests over minority value.
RichFakir rates Simplex Realty Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Simplex Realty Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Simplex Realty Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Simplex Realty Ltd's fair value is about ₹40 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →